GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenaya Therapeutics Inc (NAS:TNYA) » Definitions » Book Value per Share

Tenaya Therapeutics (Tenaya Therapeutics) Book Value per Share : $2.02 (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Tenaya Therapeutics Book Value per Share?

Tenaya Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $2.02.

During the past 12 months, Tenaya Therapeutics's average Book Value Per Share Growth Rate was -37.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Tenaya Therapeutics's current price is $4.54. Its book value per share for the quarter that ended in Mar. 2024 was $2.02. Hence, today's PB Ratio of Tenaya Therapeutics is 2.25.

During the past 5 years, the highest P/B Ratio of Tenaya Therapeutics was 3.28. The lowest was 0.00. And the median was 0.00.


Tenaya Therapeutics Book Value per Share Historical Data

The historical data trend for Tenaya Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenaya Therapeutics Book Value per Share Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
-1.62 -2.99 6.75 3.64 2.04

Tenaya Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.22 2.80 2.42 2.04 2.02

Competitive Comparison of Tenaya Therapeutics's Book Value per Share

For the Biotechnology subindustry, Tenaya Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenaya Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Tenaya Therapeutics's PB Ratio falls into.



Tenaya Therapeutics Book Value per Share Calculation

Tenaya Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(139.42-0.00)/68.33
=2.04

Tenaya Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(158.18-0.00)/78.52
=2.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Tenaya Therapeutics  (NAS:TNYA) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Tenaya Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Tenaya Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenaya Therapeutics (Tenaya Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
171 Oyster Point Boulevard, Suite 500, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Executives
Timothy Hoey officer: Chief Scientific Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, 5TH FLR., SOUTH SAN FRANCISCO CA 94080
Leone D Patterson officer: Chief Fin and Bus. Officer
Whittemore Tingley officer: Chief Medical Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Faraz Ali director, officer: Chief Executive Officer C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BLVD., 5TH FLR., SOUTH SAN FRANCISCO Z4 94080
David V Goeddel director, 10 percent owner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Iii Gp, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Amy L. Burroughs director TWO CARLSON PARKWAY, SUITE 260, MINNEAPOLIS MN 55447
Column Group Iii, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Opportunity Iii Gp, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Tcg Opportunity Iii Gp, Llc 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Column Group Opportunity Iii, Lp 10 percent owner 1 LETTERMAN DRIVE, BUILDING D, SUITE DM-900, SAN FRANCISCO CA 94129
Deepak Srivastava director C/O TENAYA THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Column Group Iii-a, Lp 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Eli Casdin director 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019